Taylor Strowman
Infectious Disease · Charleston, SCNPI 1780242834
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,574 of the $5,150 with a category attached, or 88.8%. 25 manufacturers reported payments, led by Gilead at 30.0% of the total. Reporting peaked in 2022 at $1,793 and has fallen 97.5% since, to $44 in 2025.
Across 210 payments — averaging $24.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Viiv Healthcare Company$755
- Merck$513
- AbbVie$364
- La Jolla Pharmaceutical Company$284
- Johnson & Johnson$271
- plus $1K from 19 others
What the payments were for
- Consulting fees$56011%
- Food & beverage$4,57489%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 38 | $1,545 |
| Viiv Healthcare Company | 38 | $755 |
| Merck | 20 | $513 |
| AbbVie | 21 | $364 |
| La Jolla Pharmaceutical Company | 13 | $284 |
| Johnson & Johnson | 16 | $271 |
| Astellas Pharma US Inc | 9 | $220 |
| Shionogi Inc | 7 | $191 |
| Melinta Therapeutics, LLC | 6 | $171 |
| Paratek Pharmaceuticals, Inc. | 7 | $140 |
| Napo Pharmaceuticals Inc | 6 | $110 |
| Theratechnologies Inc. | 6 | $105 |
| Insmed, Inc. | 4 | $105 |
| Ferring Pharmaceuticals Inc. | 3 | $64 |
| Cumberland Pharmaceuticals, Inc. | 3 | $62 |
| Pfizer | 2 | $40 |
| Janssen Scientific Affairs, LLC | 2 | $36 |
| Mayne Pharma Commercial LLC | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| GSK | 1 | $23 |
| Dynavax Technologies Corporation | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| EMD Serono, Inc. | 1 | $14 |
| Hydrofera LLC | 1 | $13 |
How this compares
$5,150 in reported general payments places this provider in the 80th percentile of 102 infectious disease providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 51 | $206,576 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $46,819 |
| Darunavir | 12 | $1,194 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $1,545 | $253,39563 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 102 infectious disease providers in South Carolina.
Other infectious disease in Charleston
- Toby FugateCharleston$136K
- John McKinnonCharleston$85K
- John GnannCharleston$39K
- Scott CurryCharleston$8K
- Kent StockCharleston$8K
- Cameron SelentCharleston$6K
- Eric MeissnerCharleston$4K
- Drew CharlesCharleston$2K
- Susan DormanCharleston$2K
- Joseph JohnCharleston$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.